|

EB-DNK102 dual-targeting CAR-NK cells (CLDN18.2 + MUC1) Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing Biotech1

Indications

  • Unresectable Locally Advanced or Metastatic Disease1
  • Pancreatic Ductal Adenocarcinoma (PDAC)1
  • Cancer1

Other1 trial

Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.